Hoth Therapeutics, a patient-focused biopharmaceutical company, has announced advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline.

These newly secured patents reflect Hoth's commitment to pioneering cutting-edge treatments that address unmet medical needs, with a focus on enhancing therapeutic efficacy and broadening applications across various disease areas.

"Our expanding intellectual property portfolio supports Hoth's position as a leader in innovative drug development. These provisional patent applications reinforce our proprietary approaches and our mission to deliver breakthrough therapies that improve patients' lives," said Robb Knie, CEO of Hoth Therapeutics.

Hoth Therapeutics continues to invest in robust research and development strategies, ensuring the protection and growth of its proprietary technologies. The company remains dedicated to advancing its pipeline and delivering impactful healthcare solutions.

Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. The company acts as a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing.

Utilizing a patient-centric approach, the company collaborates and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options.